Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Connect Biopharma Holdings (CNTB) Payables (2023 - 2025)

Connect Biopharma Holdings' Payables history spans 3 years, with the latest figure at $2.0 million for Q3 2025.

  • For Q3 2025, Payables changed N/A year-over-year to $2.0 million; the TTM value through Sep 2025 reached $2.0 million, changed N/A, while the annual FY2024 figure was $342000.0, 84.52% down from the prior year.
  • Payables for Q3 2025 was $2.0 million at Connect Biopharma Holdings, down from $2.3 million in the prior quarter.
  • Across five years, Payables topped out at $2.3 million in Q2 2025 and bottomed at $342000.0 in Q4 2024.
  • The 3-year median for Payables is $2.0 million (2025), against an average of $1.5 million.
  • The largest YoY upside for Payables was 84.52% in 2024 against a maximum downside of 84.52% in 2024.
  • A 3-year view of Payables shows it stood at $2.2 million in 2023, then tumbled by 84.52% to $342000.0 in 2024, then skyrocketed by 483.04% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for CNTB's Payables are $2.0 million (Q3 2025), $2.3 million (Q2 2025), and $817000.0 (Q1 2025).